

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10594373
	Filing Date		2006-09-27
	First Named Inventor	Alan Meehan	
	Art Unit	1627	
	Examiner Name	U. Ramachandran	
	Attorney Docket Number	21438P	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10594373
Filing Date	2006-09-27
First Named Inventor	Alan Meehan
Art Unit	1627
Examiner Name	U. Ramachandran
Attorney Docket Number	21438P

1	DUTASTERIDE (AVODART) PRODUCT INFORMATION, "AVODART® SOFT CAPSULES" Issue No. 3 (FEB2009) 1-11	<input type="checkbox"/>
2	ESPOSITO, K., et al., "High Proportions of Erectile Dysfunction in Men with the Metabolic Syndrome", Diabetes Care, 2:5 (2005) 1201-1203	<input type="checkbox"/>
3	GELLER, J., "Effect of Finasteride, a 5 α -Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen" J. of Clinical Endocrinology and Metabolism, 71:6 (1990) 1552-1555	<input type="checkbox"/>
4	KAPLAN, S.A., et al., "PCPT: Evidence That Finasteride Reduces Risk of Most Frequently Detected Intermediate- and High-grade (Gleason Score 6 and 7) Cancer" J. of Urology 73:5 (2009) 935-939	<input type="checkbox"/>
5	LAUKKANEN, J.A., et al., "Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study" Cancer Epidemiology, Biomarkers & Prevention 13:10, (2004) 1646-1650	<input type="checkbox"/>
6	MARKS, L.S., et al., "Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-Onset Hypogonadism" JAMA 296:19 (2006) 2351-2361	<input type="checkbox"/>
7	MCCONNELL, J.D., et al., "Finasteride, an Inhibitor of 5 α -Reductase, Suppresses Prostatic Dihydrotestosterone in Men with Benign Prostatic Hyperplasia" J. of Clinical Endocrinology and Metabolism 74:3 (1992) 505-508	<input type="checkbox"/>
8	OPPOSING VIEWS, "Should Testosterone Replacement be Given to Men with Large Prostates?" J. of Urology 182 (2009) 2109-2111	<input type="checkbox"/>
9	PAGE, S.T., et al., "Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men" J. of Clinical Endocrinology and Metabolism 91:10 (2006) 3850-3856	<input type="checkbox"/>
10	PROSCAR PRODUCT INFORMATION, "PROSCAR® (FINASTERIDE) TABLETS" (1992,1995,1998) 9631303, 1-14	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10594373
Filing Date	2006-09-27
First Named Inventor	Alan Meehan
Art Unit	1627
Examiner Name	U. Ramachandran
Attorney Docket Number	21438P

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.